• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种高通量蛋白质制剂平台:鲑鱼降钙素的案例研究

A high throughput protein formulation platform: case study of salmon calcitonin.

作者信息

Capelle Martinus A H, Gurny Robert, Arvinte Tudor

机构信息

Department of Pharmaceutics and Biopharmaceutics, School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Quai E-Ansermet 30, 1211, Geneva 4, Switzerland.

出版信息

Pharm Res. 2009 Jan;26(1):118-28. doi: 10.1007/s11095-008-9662-8. Epub 2008 Jul 4.

DOI:10.1007/s11095-008-9662-8
PMID:18600433
Abstract

PURPOSE

The feasibility of using high throughput spectroscopy for characterization and selection of physically stable protein formulations was studied.

MATERIALS AND METHODS

A hundred aqueous formulations of salmon calcitonin (sCT) were prepared using 20 buffer compositions. The solutions had pH values between 2.5 and 10.5. The stability of the sCT formulations was analyzed over 1 week by the following assays: (1) protein concentration, (2) volume control by measuring pathlength, (3) turbidity (absorbance at 350 nm), (4) intrinsic tyrosine fluorescence, (5) 1-anilino-naphthalene-8-sulfonate (ANS) fluorescence, (6) Nile Red fluorescence. Addition of the dyes (Nile Red and ANS) was used to study protein conformational changes.

RESULTS

After 1 day, 27 out of the 100 formulations of salmon calcitonin were stable. After 7 days, 12 stable sCT formulations remained. The best salmon calcitonin formulation was in 10 mM sodium acetate buffer with pH values between 3.5 and 5.5.

CONCLUSIONS

The findings are in accordance with the sCT formulations that were patented and used commercially. This can be considered as a proof of concept for the high throughput protein formulation platform.

摘要

目的

研究使用高通量光谱法对物理稳定的蛋白质制剂进行表征和筛选的可行性。

材料与方法

使用20种缓冲液组合物制备了100种鲑鱼降钙素(sCT)水性制剂。溶液的pH值在2.5至10.5之间。通过以下测定法对sCT制剂的稳定性进行了为期1周的分析:(1)蛋白质浓度,(2)通过测量光程进行体积控制,(3)浊度(350nm处的吸光度),(4)内在酪氨酸荧光,(5)1-苯胺基萘-8-磺酸盐(ANS)荧光,(6)尼罗红荧光。添加染料(尼罗红和ANS)用于研究蛋白质构象变化。

结果

1天后,100种鲑鱼降钙素制剂中有27种稳定。7天后,仍有12种稳定的sCT制剂。最佳的鲑鱼降钙素制剂是在pH值为3.5至5.5的10mM醋酸钠缓冲液中。

结论

这些发现与已获专利并商业使用的sCT制剂一致。这可被视为高通量蛋白质制剂平台的概念验证。

相似文献

1
A high throughput protein formulation platform: case study of salmon calcitonin.一种高通量蛋白质制剂平台:鲑鱼降钙素的案例研究
Pharm Res. 2009 Jan;26(1):118-28. doi: 10.1007/s11095-008-9662-8. Epub 2008 Jul 4.
2
Encapsulation into PEG-liposomes does not improve the bioavailability of pulmonary delivered salmon calcitonin.包封于 PEG-脂质体中并不会提高肺递送鲑鱼降钙素的生物利用度。
J Aerosol Med Pulm Drug Deliv. 2014 Feb;27(1):1-11. doi: 10.1089/jamp.2013.1049. Epub 2013 Nov 19.
3
Effect of lyophilization on liposomal encapsulation of salmon calcitonin.冻干对鲑鱼降钙素脂质体包封的影响。
J Liposome Res. 2014 Dec;24(4):297-303. doi: 10.3109/08982104.2014.899366. Epub 2014 Apr 8.
4
In vitro and in vivo characterisation of PEG-lipid-based micellar complexes of salmon calcitonin for pulmonary delivery.鲑鱼降钙素 PEG 脂质胶束复合物的体内外特性及其在肺部给药中的应用。
Pharm Res. 2012 Jun;29(6):1425-34. doi: 10.1007/s11095-012-0688-6. Epub 2012 Feb 10.
5
Tryptophan-mPEGs: novel excipients that stabilize salmon calcitonin against aggregation by non-covalent PEGylation.色氨酸-PEGs:通过非共价 PEG 化稳定鲑鱼降钙素聚集的新型赋形剂。
Eur J Pharm Biopharm. 2011 Nov;79(3):646-57. doi: 10.1016/j.ejpb.2011.06.003. Epub 2011 Jun 14.
6
Characterisation of salmon calcitonin in spray-dried powder for inhalation. Effect of chitosan.用于吸入的喷雾干燥粉末中鲑鱼降钙素的特性。壳聚糖的影响。
Int J Pharm. 2007 Mar 1;331(2):176-81. doi: 10.1016/j.ijpharm.2006.10.030. Epub 2006 Oct 27.
7
Formulation, stability and pharmacokinetics of sugar-based salmon calcitonin-loaded nanoporous/nanoparticulate microparticles (NPMPs) for inhalation.用于吸入的糖基化鲑鱼降钙素负载纳米多孔/纳米颗粒微粒(NPMPs)的制剂、稳定性及药代动力学
Int J Pharm. 2015 Apr 10;483(1-2):6-18. doi: 10.1016/j.ijpharm.2015.02.003. Epub 2015 Feb 3.
8
Synthesis, characterization and evaluation of bone targeting salmon calcitonin analogs in normal and osteoporotic rats.正常和骨质疏松大鼠中骨靶向鲑鱼降钙素类似物的合成、表征和评价。
J Control Release. 2012 Feb 28;158(1):44-52. doi: 10.1016/j.jconrel.2011.09.096. Epub 2011 Oct 6.
9
Ultraviolet Resonance Raman spectroscopy used to study formulations of salmon calcitonin, a starch-peptide conjugate and TGF-β3.利用紫外共振拉曼光谱研究鲑鱼降钙素、淀粉-肽缀合物和 TGF-β3 的配方。
Eur J Pharm Biopharm. 2012 Jun;81(2):392-8. doi: 10.1016/j.ejpb.2012.02.016. Epub 2012 Mar 6.
10
Salmon calcitonin-loaded Eudragit® and Eudragit®-PLGA nanoparticles: in vitro and in vivo evaluation.鲑鱼降钙素载药 Eudragit®和 Eudragit®-PLGA 纳米粒:体外与体内评价。
J Microencapsul. 2012;29(2):156-66. doi: 10.3109/02652048.2011.635426. Epub 2011 Nov 30.

引用本文的文献

1
Comparative Effects of Metal-Catalyzed Oxidizing Systems on Carbonylation and Integrity of Therapeutic Proteins.金属催化氧化系统对治疗性蛋白质羰基化和完整性的比较影响
Pharm Res. 2016 Feb;33(2):526-39. doi: 10.1007/s11095-015-1807-y. Epub 2015 Oct 23.
2
High-throughput biophysical analysis of protein therapeutics to examine interrelationships between aggregate formation and conformational stability.蛋白质治疗药物的高通量生物物理分析,以研究聚集体形成与构象稳定性之间的相互关系。
AAPS J. 2014 Jan;16(1):48-64. doi: 10.1208/s12248-013-9539-6. Epub 2013 Oct 31.
3
High-throughput screening of excipients intended to prevent antigen aggregation at air-liquid interface.

本文引用的文献

1
High throughput screening of protein formulation stability: practical considerations.蛋白质制剂稳定性的高通量筛选:实际考量
Eur J Pharm Biopharm. 2007 Feb;65(2):131-48. doi: 10.1016/j.ejpb.2006.09.009. Epub 2006 Sep 29.
2
Detection and characterization of protein aggregates by fluorescence microscopy.通过荧光显微镜检测和表征蛋白质聚集体
Int J Pharm. 2007 Feb 1;329(1-2):37-45. doi: 10.1016/j.ijpharm.2006.08.024. Epub 2006 Aug 26.
3
Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society.
高通量筛选旨在防止气液界面抗原聚集的辅料。
Pharm Res. 2011 Jul;28(7):1591-605. doi: 10.1007/s11095-011-0393-x. Epub 2011 Mar 12.
4
Fluorescent molecular rotors as dyes to characterize polysorbate-containing IgG formulations.荧光分子转子作为染料来表征含聚山梨酯的 IgG 制剂。
Pharm Res. 2010 Feb;27(2):314-26. doi: 10.1007/s11095-009-0020-2. Epub 2009 Dec 30.
绝经后女性骨质疏松症的管理:北美更年期协会2006年立场声明
Menopause. 2006 May-Jun;13(3):340-67; quiz 368-9. doi: 10.1097/01.gme.0000222475.93345.b3.
4
Point: why biogenerics make sense.
Nat Biotechnol. 2006 Mar;24(3):268-9. doi: 10.1038/nbt0306-268b.
5
SuperGenerics: a better alternative for biogenerics.超级仿制药:生物仿制药的更佳替代品。
Drug Discov Today. 2005 Apr 15;10(8):533-5. doi: 10.1016/S1359-6446(05)03410-0.
6
Induction and analysis of aggregates in a liquid IgG1-antibody formulation.液体IgG1抗体制剂中聚集体的诱导与分析
Eur J Pharm Biopharm. 2005 Apr;59(3):407-17. doi: 10.1016/j.ejpb.2004.12.004.
7
Calcitonin therapy in osteoporosis.骨质疏松症的降钙素治疗
Treat Endocrinol. 2004;3(2):117-32. doi: 10.2165/00024677-200403020-00006.
8
A fluorescence-based high-throughput assay for antimicrotubule drugs.一种基于荧光的抗微管药物高通量检测方法。
Anal Biochem. 2003 Apr 1;315(1):49-56. doi: 10.1016/s0003-2697(02)00691-7.
9
Evaluation of liquid handling conditions in microplates.
J Biomol Screen. 2001 Feb;6(1):47-56. doi: 10.1177/108705710100600107.
10
Multicenter collaborative study to calibrate salmon calcitonin by bioassay and high-performance liquid chromatography: establishment of the third international standard.通过生物测定法和高效液相色谱法校准鲑鱼降钙素的多中心合作研究:第三国际标准的建立
Bone. 2001 Jul;29(1):84-9. doi: 10.1016/s8756-3282(01)00474-4.